Core Viewpoint - BeiGene is positioned for sustainable revenue growth through the launch of new products, with a revenue target of $5.1 billion to $5.3 billion likely to be achieved [1] Group 1: Revenue Growth and Product Launch - BeiGene's cancer therapy Brukinsa is expected to continue boosting global sales in the coming years due to its best-in-class characteristics and expanding market penetration [1] - The company is entering a new development phase, projected to achieve positive profits and positive free cash flow starting in 2025 [1] Group 2: Operational Efficiency and Rating - BeiGene is anticipated to leverage its global operational platform to enhance operational efficiency and cash generation capabilities [1] - The rating for BeiGene is set at "Buy," with a target price of HKD 252 [1]

Core Viewpoint - BeiGene is expected to achieve sustainable revenue growth through the launch of new products, with a revenue target of $5.1 billion to $5.3 billion deemed highly achievable [1] Group 1: Revenue Growth Potential - Analysts from Daiwa Capital Markets believe that BeiGene's revenue target is likely to be met, supported by its global operational platform which will enhance operational efficiency and cash generation capabilities [1] - The company's cancer therapy Brukinsa is projected to continue boosting global sales in the coming years due to its best-in-class characteristics and expanding market penetration [1] Group 2: Financial Outlook - From 2025 onwards, BeiGene is expected to achieve positive profits and positive free cash flow, attributed to a more diversified revenue structure and improving profit margins [1] - Daiwa Capital Markets has assigned a "Buy" rating to the stock, with a target price set at HKD 252.00 [1]